Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.
Institute of Brain Science and Brain-Inspired Technology, West China Hospital, Sichuan University, Chengdu, China.
Eur J Neurol. 2022 Aug;29(8):2367-2375. doi: 10.1111/ene.15376. Epub 2022 May 10.
This study was undertaken to investigate the association between human leukocyte antigen (HLA) genotype and clinical characteristics of anti-LGI1 encephalitis.
HLA genotyping was performed in 34 patients with anti-LGI1 encephalitis admitted to West China Hospital between April 2014 and May 2021, as well as in 305 healthy controls. The online tool NetMHCIIpan 4.0 and AutoDock Vina software were used to predict binding between LGI1 peptide and HLA class II molecules.
Risk of anti-LGI1 encephalitis was strongly associated with the DRB103:01 allele (odds ratio [OR] = 4.31, 95% confidence interval [CI] = 1.96-9.25, corrected p = 2.75 × 10 ) and the DRB103:01-DQB102:01 haplotype (OR = 4.45, 95% CI = 2.02-9.59, corrected p = 2.94 × 10 ). Compared to carriers of the DRB107:01 allele, those with the DRB103:01 allele were more likely to be female (93.3% vs. 33.3%, p = 0.004) and to be younger (median age = 38 vs. 65 years, p < 0.001). DRB103:01 carriers showed stronger response to immunotherapy than carriers of the DRB107:01 allele, based on median score decrease on the modified Rankin scale (2, interquartile range = 1-2 vs. 1, interquartile range = 0-1; p = 0.03) at 4 weeks after immunotherapy. Prediction and docking algorithms suggested that the LGI1 peptide can bind to the DRB103:01 molecule strongly.
The strong association between anti-LGI1 encephalitis and certain HLA class II alleles supports a primary autoimmune origin for the disease. Carriers of the DRB1*03:01 allele in Chinese patients with anti-LGI1 encephalitis are more likely to be female, to suffer earlier disease onset, and to respond better to immunotherapy.
本研究旨在探讨人类白细胞抗原(HLA)基因型与抗 LGI1 脑炎临床特征之间的关系。
对 2014 年 4 月至 2021 年 5 月期间在华西医院就诊的 34 例抗 LGI1 脑炎患者及 305 例健康对照者进行 HLA 基因分型。采用 NetMHCIIpan 4.0 在线工具和 AutoDock Vina 软件预测 LGI1 肽与 HLA Ⅱ类分子的结合。
抗 LGI1 脑炎的发病风险与 DRB103:01 等位基因(比值比[OR] = 4.31,95%置信区间[CI] = 1.96-9.25,校正后 p = 2.75×10 -3 )和 DRB103:01-DQB102:01 单倍型(OR = 4.45,95%CI = 2.02-9.59,校正后 p = 2.94×10 -3 )显著相关。与携带 DRB107:01 等位基因者相比,携带 DRB103:01 等位基因者更可能为女性(93.3% vs. 33.3%,p = 0.004)和更年轻(中位年龄= 38 岁 vs. 65 岁,p<0.001)。基于改良 Rankin 量表评分中位数降低(4 周时为 2,四分位距= 1-2 比 1,四分位距= 0-1;p = 0.03),携带 DRB103:01 等位基因者对免疫治疗的反应强于携带 DRB107:01 等位基因者。预测和对接算法提示 LGI1 肽可与 DRB103:01 分子紧密结合。
抗 LGI1 脑炎与某些 HLA Ⅱ类等位基因的强相关性支持该疾病的主要自身免疫性发病机制。中国抗 LGI1 脑炎患者携带 DRB1*03:01 等位基因者更可能为女性、发病更早、对免疫治疗反应更好。